PATENT CLAIM ANALYSIS

Application Number: 15976630
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["424", "278100"]

Abstract:
Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. More specifically the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.

Claim (Index 18):
A method of ameliorating the binding and accumulation of a cellular immunotherapy in secondary lymphatic binding sites comprising:\n identifying a patient suffering from a disease selected from the group consisting of: cancer, autoimmune disease, and infection; administering to said patient adoptive cellular therapy (ACT) comprising either a cell used to enhance the immune system in treating said cancer or a cell derived from an immune lineage which directly treats said cancer; and administering a non-toxic lymphodepleting agent (NTLA), which lymphodepletes and ablates the secondary lymphatic binding sites where said cellular immunotherapy binds and accumulates, and is selected from the group consisting of: Tacrolimus delivered as an injection or oral dose of 0.48 mg/kg to about 10 mg/kg for about 1-4 weeks, Cyclosporine administered at about 15-100 mgs/kg/daily or about 7.5-50 mgs/kg/twice-daily for about 7-28 days, Dexamethasone base, or an equivalent dose of another glucocorticoid, between about 3-26 mg/kg for a single acute dose about 12-72 hours, and a TNF inhibitor administered for about 3 to about 4 weeks; wherein the administration of the NTLA occurs before or in conjunction with administration of said ACT, such as to ameliorate the binding and accumulation of said ACT cells in secondary lymphatic binding sites.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.51111
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15649369', '15167977', '13708014', '12721645', '14661656']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6722831033125728
- 35 USC 102 Novelty (BERT): 0.5149301875731215
- Combined Prediction Score: 0.6565478117386276
- Mean Citation Score: 272.19344199999995
- Max Citation Score: 285.63626
- Similarity Product: 183.0800148848844

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test